Evidence map›Paper›PMID 41542684›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Nasal Gene Expression in ART-Naive Adults with HIV and Pulmonary Tuberculosis in Uganda.

Nisreen Khambati, Kattya Lopez Tamara, Elizabeth Nakabugo, Arthur Van Valkenburg, Jessica K Anderson, Sean Lu, Rinn Song, Suryaram Gummuluru, Andrew J Pollard, Jerrold Ellner and 5 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nisreen KhambatiOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
Kattya Lopez TamaraDepartment of Medicine, Centre for Emerging Pathogens, Rutgers-New Jersey Medical School, Newark, NJ, USA.
Elizabeth NakabugoMakerere University College of Health Sciences, Kampala, Uganda.
Arthur Van ValkenburgDivision of Infectious Disease, Center for Data Science, Rutgers New Jersey Medical School, Newark, NJ, 07103, USA.
Jessica K AndersonDivision of Infectious Disease, Center for Data Science, Rutgers New Jersey Medical School, Newark, NJ, 07103, USA.
Sean LuDivision of Infectious Disease, Center for Data Science, Rutgers New Jersey Medical School, Newark, NJ, 07103, USA.
Rinn SongOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
Suryaram GummuluruDepartment of Virology, Immunology & Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston MA 02118.
Andrew J PollardOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
Jerrold EllnerDepartment of Medicine, Centre for Emerging Pathogens, Rutgers-New Jersey Medical School, Newark, NJ, USA.
Padmini SalgameDepartment of Medicine, Centre for Emerging Pathogens, Rutgers-New Jersey Medical School, Newark, NJ, USA.
Else Margreet BijkerOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
Lydia NakiyingiMakerere University College of Health Sciences, Kampala, Uganda.
Daniel O ConnorOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
W Evan JohnsonDivision of Infectious Disease, Center for Data Science, Rutgers New Jersey Medical School, Newark, NJ, 07103, USA.

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH, DEBBIE M. CHENG · 1998 to 2026
$51.7M
FEND for TB supplement to accelerate BLINK X developmentU01AI152084 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI ALLAND, DAVID, DORMAN, SUSAN E · 2020 to 2024
$20.0M
Novel and Optimized Diagnostics for Pediatric TBR01AI152159 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI ALLAND, DAVID, ELLNER, JERROLD J. · 2020 to 2024
$6.0M
Biomarker Signatures of TB Infection in Young Children With and Without HIVR01AI175315 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI Jerrold J. Ellner, William Evan Johnson · 2023 to 2026
$4.2M
Removing batch effects in high-throughput biomedical studiesR01GM127430 · NIGMS · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI William Evan Johnson · 2018 to 2026
$2.4M
Signature of profiling and staging the progression of TB from infection to disease.R21AI154387 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI JOHNSON, WILLIAM EVAN · 2020 to 2021
$468k
NIAID NIH HHS P30 AI042853NIAID NIH HHS R01 AI152159NIAID NIH HHS R01 AI175315NIAID NIH HHS R21 AI154387NIAID NIH HHS U01 AI152084NIGMS NIH HHS R01 GM127430
6 · The paper itself

Abstract

Background: Diagnosis of pulmonary tuberculosis (TB) in people living with HIV remains difficult. Since the first pathogen-host interaction in TB occurs in the upper airway, we hypothesized that host transcriptomic analysis on nasal specimens may identify novel diagnostic biomarkers. We aimed to demonstrate differences in nasal gene expression between people with HIV and TB disease versus people with HIV without TB, evaluate the performance of nasal signatures in classifying TB and compare nasal gene profiles with blood gene profiles from the same cohort. Methods: We enrolled adults in Uganda with newly diagnosed HIV and symptoms of pulmonary TB disease We collected nasal cells and blood for RNA sequencing to identify differentially expressed genes and enriched pathways between people with HIV and TB disease and people with HIV without TB. Supervised machine-learning of gene expression data was used to predict TB status. Results: 40 adults living with HIV were enrolled (median age: 34 years, median CD4 count: 182), including 20 with TB disease and 20 without. We identified 44 nasal differentially expressed genes and 238 blood differentially expressed genes, with three overlapping genes between sample types. Models trained using all 44 nasal differentially expressed genes had a cross-validated area under the curve between 0.87-0.90 for predicting TB disease amongst adults living with HIV. A simplified four-gene signature ( Conclusion: This proof-of-concept study demonstrated that there were distinct nasal gene expression patterns associated with TB, not seen in blood. Differences in nasal gene expression in people with HIV who have TB disease, versus those without TB, highlight their potential as diagnostic biomarkers. Further validation studies of gene signatures using minimally invasive nasal samples are recommended in other difficult to diagnose groups.

Indexed as

diagnosisHIVnasaltranscriptomicstuberculosis

Identifiers

PMID41542684
PMCPMC12803297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.